More than 300 people are expected to descend on the University of Aberdeen tomorrow night (September 16) for a talk by a scientist who announced in the summer news of an Alzheimer’s breakthrough.
Professor Claude Wischik made headlines across the world in July when he and his research team revealed the results of a trial of a new treatment for Alzheimer's disease.
The Professor of Psychiatric Geratology and Old Age Psychiatry at the University of Aberdeen described how a Phase 2 trial of the drug rember™ appears to slow the progress of the disorder by 81% over a year.
The new therapy was developed by Professor Wischik's research team, together with TauRx Therapeutics, which is a Singapore based company spun out of the University.
Professor Wischik, who is Chairman of TauRx Therapeutics, will outline details of the trial at tomorrow night's Alzheimer's Research Trust public lecture which is taking place at 6pm at the University's Arts Lecture Theatre.
Places are still available at the lecture which is free and open to all. To reserve a seat at the event contact Karen Scaife at the University of Aberdeen Events Office on 01224 273233 or email href="mailto:events@abdn.ac.uk" title="mailto:events@abdn.ac.uk">events@abdn.ac.uk</a></p>
PLEASE NOTE: The Phase 2 clinical trial has now ended. A Phase 3 clinical trial is planned for next year. Recruitment has not begun and it is not yet known where the trial will take place. rember™ is not available on the market.